Keefe Bruyette analyst Sanjay Sakhrani lowered the firm’s price target on Bill (BILL) to $77 from $95 and keeps a Market Perform rating on the shares. The firm remains on the sidelines until there are more tangible signs of growth, the analyst tells investors in a research note.